In other cases like domestic bispecific antibody targeting DLL3 and CD3 (QLS31904) has proved to exert marked inhibitory effects on tumor growth in preclinical models, with phase I studies (NCT05461287) evaluating the safety, tolerability, and pharmacokinetics of QLS31904 in patients with advanced solid tumors under active cultivation. The gene discussed is DLL3; the disease is neoplasm.